Related Experiment Video
Updated: Jun 12, 2025
A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood
Published on: April 28, 2016
GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective
Mateus D'Ávila1,2, Samantha Hall1, Tamas L Horvath1,2
1Department of Comparative Medicine, Yale School of Medicine, New Haven, CT 06520, USA.
Abstract:
For centuries, increasingly sophisticated methods and approaches have been brought to bear to promote weight loss. Second only to the Holy Grail of research on aging, the idea of finding a single and simple way to lose weight has long preoccupied the minds of laymen and scientists alike. The effects of obesity are far-reaching and not to be minimized; the need for more effective treatments is obvious. Is there a single silver bullet that addresses this issue without effort on the part of the individual? The answer to this question has been one of the most elusive and sought-after in modern history. Now and then, a miraculous discovery propagates the illusion that a simple solution is possible. Now there are designer drugs that seem to accomplish the task: we can lose weight without effort using mono, dual, and triple agonists of receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon. There are, however, fundamental biological principles that raise intriguing questions about these therapies beyond the currently reported side-effects. This perspective reflects upon these issues from the angle of complex goal-oriented behaviors, and systemic and cellular metabolism associated with satiety and hunger.
Insights
Designer drugs targeting GLP-1, GIP, and glucagon receptors offer effortless weight loss. However, fundamental biological principles prompt deeper questions about these therapies beyond known side effects.
Area of Science:
- Metabolic research
- Obesity treatment
- Behavioral science
Background:
- Obesity presents significant health challenges, driving the search for effective weight loss solutions.
- Despite extensive research, a simple, universally effective weight loss method remains elusive.
- Recent advancements include designer drugs acting as agonists for GLP-1, GIP, and glucagon receptors.
Purpose of the Study:
- To critically examine the biological underpinnings of novel weight loss therapies.
- To explore the implications of complex goal-oriented behaviors on weight management.
- To investigate the systemic and cellular metabolic factors influencing satiety and hunger in the context of these drugs.
Main Methods:
- Perspective review of current scientific literature.
- Analysis of pharmacological mechanisms of mono-, dual-, and triple-agonist therapies.
- Consideration of metabolic and behavioral science principles.
Main Results:
- Designer drugs offer a seemingly effortless approach to weight loss.
- These therapies engage receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon.
- Fundamental biological principles raise questions regarding long-term efficacy and broader implications.
Conclusions:
- While novel weight loss drugs show promise, a comprehensive understanding of their impact on complex biological systems is crucial.
- Further research is needed to explore the interplay between these drugs, goal-oriented behaviors, and metabolic regulation.
- A holistic view integrating cellular metabolism, satiety, and behavior is essential for advancing obesity treatment.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
01:06Oral Hypoglycemic Agents: Glinides
01:23Dipeptidyl Peptidase 4 Inhibitors
01:30Regulation of Food Intake
01:15Hypoglycemia and Glucagon
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...